312 related articles for article (PubMed ID: 19052714)
1. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
[TBL] [Abstract][Full Text] [Related]
2. [TP53 codon 72 polymorphism and gastric cancer risk: a case-control study in individuals from the central-western region of Venezuela].
Cañas M; Morán Y; Camargo ME; Rivero MB; Bohórquez A; Villegas V; Ramírez E; Rendón Y; Suárez A; Morales L; Useche E; Salazar S; Zambrano A; Ramírez A; Valderrama E; Briceño Z; Chiurillo MA
Invest Clin; 2009 Jun; 50(2):153-61. PubMed ID: 19662811
[TBL] [Abstract][Full Text] [Related]
3. TP53 Codon 72 Polymorphism Predicts Efficacy of Paclitaxel Plus Capecitabine Chemotherapy in Advanced Gastric Cancer Patients.
Zha Y; Gan P; Liu Q; Yao Q
Arch Med Res; 2016 Jan; 47(1):13-8. PubMed ID: 26696550
[TBL] [Abstract][Full Text] [Related]
4. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
[TBL] [Abstract][Full Text] [Related]
5. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
[TBL] [Abstract][Full Text] [Related]
6. Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma.
Zhang ZW; Newcomb P; Hollowood A; Feakins R; Moorghen M; Storey A; Farthing MJ; Alderson D; Holly J
Clin Cancer Res; 2003 Jun; 9(6):2151-6. PubMed ID: 12796380
[TBL] [Abstract][Full Text] [Related]
7. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
8. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
9. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
10. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
Licitra L; Suardi S; Bossi P; Locati LD; Mariani L; Quattrone P; Lo Vullo S; Oggionni M; Olmi P; Cantù G; Pierotti MA; Pilotti S
J Clin Oncol; 2004 Dec; 22(24):4901-6. PubMed ID: 15611505
[TBL] [Abstract][Full Text] [Related]
11. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
Santos AM; Sousa H; Portela C; Pereira D; Pinto D; Catarino R; Rodrigues C; Araújo AP; Lopes C; Medeiros R
Biochem Biophys Res Commun; 2006 Feb; 340(1):256-62. PubMed ID: 16364249
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Goekkurt E; Hoehn S; Wolschke C; Wittmer C; Stueber C; Hossfeld DK; Stoehlmacher J
Br J Cancer; 2006 Jan; 94(2):281-6. PubMed ID: 16317430
[TBL] [Abstract][Full Text] [Related]
14. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
15. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Qureshi KN; Griffiths TR; Robinson MC; Marsh C; Roberts JT; Hall RR; Lunec J; Neal DE
Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
[TBL] [Abstract][Full Text] [Related]
16. p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia.
Malisic E; Jankovic R; Slavkovic D; Milovic-Kovacevic M; Radulovic S
J BUON; 2010; 15(1):101-6. PubMed ID: 20414935
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
[TBL] [Abstract][Full Text] [Related]
18. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan.
Kuraoka K; Matsumura S; Sanada Y; Nakachi K; Imai K; Eguchi H; Matsusaki K; Oue N; Nakayama H; Yasui W
Oncol Rep; 2005 Aug; 14(2):465-70. PubMed ID: 16012731
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
Ruzzo A; Graziano F; Kawakami K; Watanabe G; Santini D; Catalano V; Bisonni R; Canestrari E; Ficarelli R; Menichetti ET; Mari D; Testa E; Silva R; Vincenzi B; Giordani P; Cascinu S; Giustini L; Tonini G; Magnani M
J Clin Oncol; 2006 Apr; 24(12):1883-91. PubMed ID: 16622263
[TBL] [Abstract][Full Text] [Related]
20. TP53 codon 72 polymorphism contributes to nasopharyngeal cancer susceptibility: a meta-analysis.
Zhuo XL; Cai L; Xiang ZL; Zhuo WL; Wang Y; Zhang XY
Arch Med Res; 2009 May; 40(4):299-305. PubMed ID: 19608020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
